Geneos vaccine shows efficacy in reducing liver tumors in trial [Video]

A third of patients with advanced liver cancer who received a personalized vaccine in a small trial saw tumors shrink. Geneos Therapeutics has announced the publication of positive safety, immunogenicity, and efficacy data in Nature Medicine.

According to the study, hepatocellular carcinoma is the most common form of primary liver cancer. It is also a leading cause of cancer-related death worldwide. Only in the United States, it is responsible for over 12,000 deaths per year. Even if there are advancements in systemic therapy for advanced hepatocellular carcinoma, the 5-year survival rate remains below 10%.

The study

The first and last patients were enrolled respectively on June 16, 2020, and June 14, 2023. All 36 patients had their personalized vaccine product.

As explained, …